14 December 2013 - BMS & AstraZeneca have pulled their diabetes treatment Forxiga (dapagliflozin) from the German market after the companies couldn’t reach an agreement with local authorities over the price of the drug. The German Federal Joint Committee gave the treatment a “no additional benefit” rating, and the companies said they couldn’t agree on a price with health-insurance administrators there. They’re in an arbitration process with German authorities, and until that’s resolved, will stop supplying the drug starting December 15.

For more details, go to: http://www.bloomberg.com/news/2013-12-13/bristol-myers-pulls-diabetes-drug-from-germany-in-price-fight.html